PTGX 10-Q: SEC filing
Protagonist Therapeutics
Filed with the SEC on · accession 0001104659-26-123620
PTGX filed a 10-Q (quarterly report) with the SEC on Nov 6, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.
Summary of the filing
Protagonist Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing routine financial results and updates on its license and collaboration agreements with Takeda and Janssen.
Key details
✦ Ask GOAX AI about this filing — what it means for PTGX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PTGX?
Click hereFrequently asked questions
What did PTGX file with the SEC on Nov 6, 2026?
PTGX filed a 10-Q (SEC filing). Protagonist Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing routine financial results and updates on its license and collaboration agreements with Takeda and Janssen.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other PTGX SEC filings
Get alerts when PTGX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days